medigraphic.com

2015, Número 2

<< Anterior Siguiente >>

Med Sur 2015; 22 (2)


E. coli BLEE, la enterobacteria que ha atravesado barreras

Aguilar-Zapata D

Idioma: Español
Referencias bibliográficas: 35
Paginas: 57-63
Archivo PDF: 213.87 Kb.


RESUMEN

Las enterobacterias han surgido como agentes causales de infecciones nosocomiales y adquiridas en la comunidad. La Escherichia coli (E. coli) es el microorganismo más frecuente de este grupo de bacterias que ha logrado generar resistencia a los antimicrobianos gracias a la generación de betalactamasas de espectro extendido (BLEE), y han surgido como causa de infecciones drogo-resistentes adquiridas en la comunidad. Los carbapenémicos son hoy día la primera opción terapéutica hacia la E. coli BLEE; sin embargo, se requiere reforzar las estrategias que acompañen la terapéutica antimicrobiana ante este germen que representa una amenaza global para la salud.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8(3): 159-66.

  2. Oteo J, Perez-Vazquez M, Campos J. Extended-spectrum [beta]-lactamase producing Escherichia coli: changing epidemiology and clinical impact. Curr Opin Infect Dis 2010; 23(4): 320-6.

  3. Daoud Z, Salem Sokhn E, Masri K, Matar GM, Doron S. Escherichia coli Isolated from Urinary Tract Infections of Lebanese Patients between 2005 and 2012: Epidemiology and Profiles of Resistance. Front Med (Lausanne) 2015; 2: 26.

  4. Metz-Gercek S, Maieron A, Strauss R, Wieninger P, Apfalter P, Mittermayer H. Ten years of antibiotic consumption in ambulatory care: trends in prescribing practice and antibiotic resistance in Austria. BMC Infect Dis 2009; 9: 61.

  5. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14(4): 933-51.

  6. Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006; 9(5): 466-75.

  7. Woodford N, Ward ME, Kaufmann ME, Turton J, Fagan EJ, James D, et al. Community and hospital spread of Escherichia coli producing CTX-M extended-spectrum beta-lactamases in the UK. J Antimicrob Chemother 2004; 54(4): 735-43.

  8. Livermore DM. Fourteen years in resistance. Int J Antimicrob Agents 2012; 39(4): 283-94.

  9. Sasaki T, Hirai I, Niki M, Nakamura T, Komalamisra C, Maipanich W, et al. High prevalence of CTX-M beta-lactamase-producing Enterobacteriaceae in stool specimens obtained from healthy individuals in Thailand. J Antimicrob Chemother 2010; 65(4): 666-8.

  10. Tian SF, Chen BY, Chu YZ, Wang S. Prevalence of rectal carriage of extended-spectrum beta-lactamase-producing Escherichia coli among elderly people in community settings in China. Can J Microbiol 2008; 54(9): 781-5.

  11. Vinue L, Saenz Y, Martinez S, Somalo S, Moreno MA, Torres C, et al. Prevalence and diversity of extended-spectrum beta-lactamases in faecal Escherichia coli isolates from healthy humans in Spain. Clin Microbiol Infect 2009; 15(10): 954-7.

  12. Valenza G, Nickel S, Pfeifer Y, Eller C, Krupa E, Lehner-Reindl V, et al. Extended-spectrum-beta-lactamase-producing Escherichia coli as intestinal colonizers in the German community. Antimicrob Agents Chemother 2014; 58(2): 1228-30.

  13. Echeverria J. Situación actual de las infecciones de vías urinarias comunitarias en un hospital de tercer nivel privado. Importancia de los organismos productores de betalactamasas de espectro extendido: Universidad Autónoma de México (UNAM); 2014.

  14. Dhanji H, Murphy NM, Doumith M, Durmus S, Lee SS, Hope R, et al. Cephalosporin resistance mechanisms in Escherichia coli isolated from raw chicken imported into the UK. J Antimicrob Chemother 2010; 65(12): 2534-7.

  15. Warren RE, Ensor VM, O’Neill P, Butler V, Taylor J, Nye K, et al. Imported chicken meat as a potential source of quinoloneresistant Escherichia coli producing extended-spectrum betalactamases in the UK. J Antimicrob Chemother 2008; 61(3): 504-8.

  16. Snow LC, Wearing H, Stephenson B, Teale CJ, Coldham NG. Investigation of the presence of ESBL-producing Escherichia coli in the North Wales and West Midlands areas of the UK in 2007 to 2008 using scanning surveillance. Vet Rec 2011; 169(25): 656.

  17. Randall LP, Clouting C, Horton RA, Coldham NG, Wu G, Clifton- Hadley FA, et al. Prevalence of Escherichia coli carrying extended- spectrum beta-lactamases (CTX-M and TEM-52) from broiler chickens and turkeys in Great Britain between 2006 and 2009. J Antimicrob Chemother 2011; 66(1): 86-95.

  18. Leverstein-van Hall MA, Dierikx CM, Cohen Stuart J, Voets GM, van den Munckhof MP, van Essen-Zandbergen A, et al. Dutch patients, retail chicken meat and poultry share the same ESBL genes, plasmids and strains. Clin Microbiol Infect 2011; 17(6): 873-80.

  19. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, et al. Bacteraemia due to extended-spectrum betalactamase- producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 2010; 65(2): 333-41.

  20. Cornejo-Juarez P, Perez-Jimenez C, Silva-Sanchez J, Velazquez- Acosta C, Gonzalez-Lara F, Reyna-Flores F, et al. Molecular analysis and risk factors for Escherichia coli producing extendedspectrum beta-lactamase bloodstream infection in hematological malignancies. PLoS One 2012; 7(4): e35780.

  21. Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV. Incidence of fluoroquinolone- resistant and extended-spectrum beta-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy 2011; 57(4): 335-8.

  22. Johnson JR, Johnston B, Clabots C, Kuskowski MA, Castanheira M. Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 2010; 51(3): 286-94.

  23. Cheng WL, Hsueh PR, Lee CC, Li CW, Li MJ, Chang CM, et al. Bacteremic pneumonia caused by extended-spectrum beta-lactamase- producing Escherichia coli and Klebsiella pneumoniae: Appropriateness of empirical treatment matters. J Microbiol Immunol Infect 2014.

  24. Wiegand I, Geiss HK, Mack D, Sturenburg E, Seifert H. Detection of extended-spectrum beta-lactamases among Enterobacteriaceae by use of semiautomated microbiology systems and manual detection procedures. J Clin Microbiol 2007; 45(4): 1167-74.

  25. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18(4): 657-86.

  26. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56(1): 52-9.

  27. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32(8): 1162-71.

  28. Tumbarello M, Sanguinetti M, Montuori E, Trecarichi EM, Posteraro B, Fiori B, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamaseproducing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51(6): 1987-94.

  29. Paterson DL. Recommendation for treatment of severe infections caused by Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs). Clin Microbiol Infect 2000; 6(9): 460-3.

  30. Del Mar Tomas M, Cartelle M, Pertega S, Beceiro A, Llinares P, Canle D, et al. Hospital outbreak caused by a carbapenemresistant strain of Acinetobacter baumannii: patient prognosis and risk-factors for colonisation and infection. Clin Microbiol Infect 2005; 11(7): 540-6.

  31. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE. Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enterobacteriaceae infections: a systematic review. Lancet Infect Dis 2010; 10(1): 43-50.

  32. Docobo-Perez F, Drusano GL, Johnson A, Goodwin J, Whalley S, Ramos-Martin V, et al. Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance. Antimicrob Agents Chemother 2015.

  33. Diario Oficial de la Federación (Federación DOdl). Acuerdo por el que se determinan los lineamientos a los que estará sujeta la venta y dispensación de antibióticos 2010 [27/05/ 2010].

  34. Ellingson K, Haas JP, Aiello AE, Kusek L, Maragakis LL, Olmsted RN, et al. Strategies to prevent healthcare-associated infections through hand hygiene. Infect Control Hosp Epidemiol 2014; 35(8): 937-60.

  35. Dellit TH, Owens RC, McGowan JE, Jr., Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44(2): 159-77.




2020     |     www.medigraphic.com